Why the study?
Atrial fibrillation incidence and prevalence are increasing globally, requiring updated evidence-based recommendations to guide clinicians in diagnosis and management.
The 2023 ACC/AHA/ACCP/HRS guideline provides updated, evidence-based recommendations for the comprehensive management of atrial fibrillation.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Although current guidelines such as those from the European Society of Cardiology and the American College of Cardiology/American Heart Association emphasize the benefits of exercise and CRF in relation to [AFib] risk, uncertainties remain concerning the role of high intensity exercise and high l...”
Establishes lifestyle modification and early rhythm control as pillars of AF care; extends prior guidance by upgrading ablation to Class 1 for selected patients.
AIM The "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Patients With Atrial Fibrillation" provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation. METHODS A comprehensive literature search was conducted from May 12, 2022, to November 3, 2022, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate. STRUCTURE Atrial fibrillation is the most sustained common arrhythmia, and its incidence and prevalence are increasing in the United States and globally. Recommendations from the "2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation" and the "2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation" have been updated with new evidence to guide clinicians. In addition, new recommendations addressing atrial fibrillation and thromboembolic risk assessment, anticoagulation, left atrial appendage occlusion, atrial fibrillation catheter or surgical ablation, and risk factor modification and atrial fibrillation prevention have been developed.
No takes yet. Share an insight, caveat, or question.
Joglar et al. (2023) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: